Indiana grandma gets Caitlin Clark surpriseTrump’s lawyers rebuff DA’s idea for upholding his hush money conviction, calling it ‘absurd’IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNITM assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number instability (CNI) is a scientifically well-known hallmark of cancer. DetermaCNITM is a patented approach to measuring CNI for the diagnosis and monitoring of cancer. Nearly 300,000 patients in the U.S. each year face primary brain tumors or brain metastasis 1 . The current standard of care for the confirmation and classification of brain tumors often involves high-risk, highly invasive biopsy of brain tissue. Thus, a liquid biopsy method for diagnosing brain tumors could offer significant benefits over currently available methods, representing a potential $300 million U.S. market opportunity. Among the study authors were Oncocyte Chief Science Officer Ekke Schuetz and Senior R&D Director Julia Beck. “This was a proof of principle study to assess whether copy number instability could be measured in the cerebrospinal fluid of patients with brain cancer. The findings suggest that a significant number of the nearly 300,000 patients diagnosed with brain tumors every year in the U.S. could benefit from DetermaCNI,” Dr. Schuetz said. “We congratulate the research team in Frankfurt on the publication of this study in an area of high unmet need.” As noted in the paper, the gold standard for precise diagnostic classification of brain tumors requires a biopsy, with risks including limited sensitivity and failing to measure the diverse potential regions of the tumor. SCNAs were observed in the cerebrospinal fluid of ten out of the 12 patients with confirmed central nervous system cancers. SCNAs were not observed in any of the 11 patients with benign or unclear central nervous system lesions. The detection of SCNAs is highly specific for tumor-derived cell-free DNA (cfDNA). Overall, this new study demonstrates DetermaCNI’s potential for providing a molecularly informed diagnosis of central nervous system cancers, mapping tumor heterogeneity, tracking tumor evolution, and surveilling tumor patients through a liquid biopsy of cerebrospinal fluid. Oncocyte believes this study validates the future clinical potential for DetermaCNI, as well as the direction of the company’s research and development pipeline, which is designed to drive sustained rapid growth over the next decade. Oncocyte’s mission is to democratize access to molecular diagnostic testing to improve patient outcomes. The company is investing in developing products to serve the separate verticals of organ transplant testing and oncology. Oncocyte is presently commercializing its transplant product line, which includes the VitaGraftTM and GraftAssureTM tests. It expects to commercialize its oncology assays over the next two years. _______________ 1 “Brain Metastases.” MD Anderson Cancer Center , www.mdanderson.org/cancer-types/brain-metastases.html. And “Brain Tumor Facts.” National Brain Tumor Society , 20 Feb. 2024, braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-facts/. About Oncocyte Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraftTM is a clinical blood-based dd-cfDNA solid organ transplantation monitoring test. GraftAssureTM is a research use only (RUO) blood-based solid dd-cfDNA organ transplantation monitoring test kit for decentralized use. DetermaIOTM is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNITM is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/ . For more information about our products, please visit the following web pages: VitaGraft KidneyTM - https://oncocyte.com/vitagraft-kidney/ VitaGraft Liver TM - https://oncocyte.com/vitagraft-liver/ GraftAssureTM - https://oncocyte.com/graftassure/ DetermaIOTM - https://oncocyte.com/determa-io/ DetermaCNITM - https://oncocyte.com/determa-cni/ VitaGraftTM, GraftAssureTM, DetermaIOTM, and DetermaCNITM are trademarks of Oncocyte Corporation. CONTACT: Jeff Ramson PCG Advisory (646) 863-6893 jramson@pcgadvisory.com Forward-Looking Statements Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the belief that the new study validates the future clinical potential for DetermaCNI, as well as the direction of the company’s research and development pipeline, the expectation that Oncocyte will commercialize its oncology assays over the next two years, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte’s third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
At Least 37 US Lawmakers Traded Up to $113 Million in Arms Stocks This YearVancouver stabbing leaves 'multiple' injured in city's downtown
Chance of direct attack by Russia ‘remote’, says UK armed forces chief
PORTLAND, Maine (AP) — A pair of conservative groups on Friday challenged a Maine law that limits donations to political action committees that spend independently in candidate elections, arguing that money spent to support political expression is "a vital feature of our democracy.” Supporters of the referendum overwhelmingly approved on Election Day fully expected a legal showdown over caps on individual contributions to so-called super PACs. They hoped the referendum would trigger a case and ultimately prompt the U.S. Supreme Court to clarify the matter of donor limits after the court opened the floodgates to independent spending in its 2010 Citizens United decision. The lawsuit brought by Dinner Table Action and For Our Future, and supported by the Institute for Free Speech, contends the state law limiting individual super PAC donations to $5,000 and requiring disclosure of donor names runs afoul of that Citizens United legal precedent. “All Americans, not just those running for office, have a fundamental First Amendment right to talk about political campaigns,” lawyers wrote in the lawsuit in federal court. “Their ‘independent expenditures,’ payments that fund political expression by those who are not running for office but nonetheless have something to say about a campaign, are a vital feature of our democracy.” Cara McCormick, leader of the Maine Citizens to End Super PACs, which pressed for the referendum, said the lawsuit attempts to undermine the will of the people after an overwhelming majority — 74% of voters — approved the referendum last month. “Super PACs are killing the country and in Maine we decided to do something about it. We want to restore public trust in the political process,” she said. “We want to say that in Maine we are not resigned to the tide of big money. We are the tide.” But Alex Titcomb, executive director of Dinner Table Action, argued Friday that the government “cannot restrict independent political speech simply because some voters wish to limit the voices of their fellow citizens.” Named in the lawsuit are Maine’s attorney general and the state’s campaign spending watchdog, the Maine Commission on Governmental Ethics and Election Practices. The ethics commission is reviewing the complaint, said Jonathan Wayne, executive director. The Maine referendum didn’t attempt to limit spending on behalf of candidates. Instead, it focused on limits on individual donations to super PACS, an area the Supreme Court has not ruled on, observers say. Harvard Law School professor Lawrence Lessig, a longtime advocate for campaign finance reform, contends the U.S. Supreme Court has not ruled on the issue of individual contributions to PACs, and long-established case law supports the notion that states can limit individual contributions to PACs despite a decision to the contrary by the Court of Appeals for the District of Columbia. Lessig, whose Equal Citizens nonprofit backed the Maine referendum, previously said the cap on donations imposed by the referendum "is not asking the Supreme Court to change its jurisprudence, not asking them to overturn Citizens United.”
WESTCHESTER, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Today, the board of directors of Ingredion Incorporated (NYSE: INGR) declared a quarterly dividend of $0.80 per share on the Company’s common stock. The dividend is payable on Jan. 21, 2025, to stockholders of record at the close of business on Jan. 2, 2025. About the Company Ingredion Incorporated (NYSE: INGR), headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in nearly 120 countries. With 2023 annual net sales of approximately $8 billion, the Company turns grains, fruits, vegetables, and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing and industrial markets. With Ingredion Idea Labs ® innovation centers located around the world and more than 12,000 employees, the Company co-creates with customers and fulfills its purpose of bringing the potential of people, nature, and technology together to make life better. Visit ingredion.com for more information and the latest Company news.
BOSTON , Dec. 13, 2024 /PRNewswire/ -- The China Fund, Inc. (NYSE: CHN) (the "Fund") announced today that the Fund's annual stockholder meeting (the "Meeting") will be scheduled for Thursday, March 13, 2025 , via a virtual forum at 11:00 a.m. ET . Stockholders of record as of January 15, 2025 will be entitled to notice of, and to attend and vote at, the Meeting. The notice for the Meeting will be mailed to shareholders on or about February 10, 2025 . The Fund is a closed-end management investment company with the objective of seeking long-term capital appreciation by investing primarily in equity securities (i) of companies for which the principal securities trading market is in the People's Republic of China (" China "), or (ii) of companies for which the principal securities trading market is outside of China , or constituting direct equity investments in companies organized outside of China , that in both cases derive at least 50% of their revenues from goods and services sold or produced, or have at least 50% of their assets, in China . While the Fund is permitted to invest in direct equity investments of companies organized in China , it presently holds no such investments. Shares of the Fund are listed on the New York Stock Exchange under the ticker symbol "CHN". The Fund's investment manager is Matthews International Capital Management, LLC. For further information regarding the Fund and the Fund's holdings, please call (888)-CHN-CALL (246-2255) or visit the Fund's website at www.chinafundinc.com . View original content: https://www.prnewswire.com/news-releases/the-china-fund-inc-announces-date-of-annual-meeting-of-stockholders-302331705.html SOURCE The China Fund, Inc.
Fall is the best time to think about cooking soup. Here’s 5 recipes you’ll want to try
BOSTON , Dec. 13, 2024 /PRNewswire/ -- The China Fund, Inc. (NYSE: CHN) (the "Fund") announced today that the Fund's annual stockholder meeting (the "Meeting") will be scheduled for Thursday, March 13, 2025 , via a virtual forum at 11:00 a.m. ET . Stockholders of record as of January 15, 2025 will be entitled to notice of, and to attend and vote at, the Meeting. The notice for the Meeting will be mailed to shareholders on or about February 10, 2025 . The Fund is a closed-end management investment company with the objective of seeking long-term capital appreciation by investing primarily in equity securities (i) of companies for which the principal securities trading market is in the People's Republic of China (" China "), or (ii) of companies for which the principal securities trading market is outside of China , or constituting direct equity investments in companies organized outside of China , that in both cases derive at least 50% of their revenues from goods and services sold or produced, or have at least 50% of their assets, in China . While the Fund is permitted to invest in direct equity investments of companies organized in China , it presently holds no such investments. Shares of the Fund are listed on the New York Stock Exchange under the ticker symbol "CHN". The Fund's investment manager is Matthews International Capital Management, LLC. For further information regarding the Fund and the Fund's holdings, please call (888)-CHN-CALL (246-2255) or visit the Fund's website at www.chinafundinc.com . View original content: https://www.prnewswire.com/news-releases/the-china-fund-inc-announces-date-of-annual-meeting-of-stockholders-302331705.html SOURCE The China Fund, Inc.
NEW YORK (AP) — lawyers urged a judge again Friday to throw out his hush money conviction, balking at the prosecution’s suggestion of preserving the verdict by treating the case the way some courts do when a defendant dies. They called the idea “absurd.” The Manhattan district attorney’s office is asking Judge Juan M. Merchan to “pretend as if one of the assassination attempts against President Trump had been successful,” Trump’s lawyers wrote in a blistering 23-page response. In court papers made public Tuesday, office proposed an array of options for keeping the historic conviction on the books after Trump’s lawyers filed paperwork earlier this month asking for the case to be dismissed. They include freezing the case until Trump leaves office in 2029, agreeing that any future sentence won’t include jail time, or closing the case by noting he was convicted but that he wasn’t sentenced and his appeal wasn’t resolved because of presidential immunity. Trump lawyers Todd Blanche and Emil Bove reiterated Friday their position that the only acceptable option is overturning his conviction and dismissing his indictment, writing that anything less will interfere with the transition process and his ability to lead the country. The Manhattan district attorney’s office declined comment. It’s unclear how soon Merchan will decide. He could grant Trump’s request for dismissal, go with one of the prosecution’s suggestions, wait until a federal appeals court rules on Trump’s parallel effort to get the case moved out of state court, or choose some other option. In their response Friday, Blanche and Bove ripped each of the prosecution’s suggestions. Halting the case until Trump leaves office would force the incoming president to govern while facing the “ongoing threat” that he’ll be sentenced to imprisonment, fines or other punishment as soon as his term ends, Blanche and Bove wrote. Trump, a Republican, takes office Jan. 20. “To be clear, President Trump will never deviate from the public interest in response to these thuggish tactics,” the defense lawyers wrote. “However, the threat itself is unconstitutional.” The prosecution’s suggestion that Merchan could mitigate those concerns by promising not to sentence Trump to jail time on presidential immunity grounds is also a non-starter, Blanche and Bove wrote. The immunity statute requires dropping the case, not merely limiting sentencing options, they argued. Blanche and Bove, both of whom Trump has tabbed for high-ranking Justice Department positions, expressed outrage at the prosecution’s novel suggestion that Merchan borrow from Alabama and other states and treat the case as if Trump had died. Blanche and Bove accused prosecutors of ignoring New York precedent and attempting to “fabricate” a solution “based on an extremely troubling and irresponsible analogy between President Trump” who survived assassination attempts in Pennsylvania in July and Florida in September “and a hypothetical dead defendant.” Such an option normally comes into play when a defendant dies after being convicted but before appeals are exhausted. It is unclear whether it is viable under New York law, but prosecutors suggested that Merchan could innovate in what’s already a unique case. “This remedy would prevent defendant from being burdened during his presidency by an ongoing criminal proceeding,” prosecutors wrote in their filing this week. But at the same time, it wouldn’t “precipitously discard” the “meaningful fact that defendant was indicted and found guilty by a jury of his peers.” Prosecutors acknowledged that “presidential immunity requires accommodation” during Trump’s impending return to the White House but argued that his election to a second term should not upend the jury’s verdict, which came when he was out of office. Longstanding Justice Department policy says sitting presidents cannot face . Other world leaders don’t enjoy the same protection. For example, is even as he leads that nation’s wars in and . Trump has been fighting for months to reverse his May 30 conviction on . Prosecutors said he fudged the documents to conceal a $130,000 payment to porn actor to suppress her claim that they had sex a decade earlier, which Trump denies. In their filing Friday, Trump’s lawyers citing a social media post in which Sen. used profane language to criticize Trump’s hush money prosecution. The Pennsylvania Democrat suggested that Trump deserved a pardon, comparing his case to that of pardoned son Hunter Biden, who had been convicted of . “Weaponizing the judiciary for blatant, partisan gain diminishes the collective faith in our institutions and sows further division,” Fetterman wrote Wednesday on Truth Social. Trump’s hush money conviction was in state court, meaning a presidential pardon — issued by Biden or himself when he takes office — would not apply to the case. Presidential pardons only apply to federal crimes. Since the election, special counsel has , which pertained to Trump’s efforts to overturn his 2020 election loss and allegations that he hoarded classified documents at his Mar-a-Lago estate. A separate in Fulton County, Georgia, is largely on hold. Trump denies wrongdoing in all. Trump had been scheduled for sentencing in the hush money case in late November. But following Trump’s Nov. 5 election victory, Merchan halted proceedings and indefinitely postponed the former and future president’s sentencing so the defense and prosecution could weigh in on the future of the case. Merchan also delayed a decision on Trump’s to dismiss the case on immunity grounds. A dismissal would erase Trump’s conviction, sparing him the cloud of a criminal record and possible prison sentence. Trump is the first former president to be convicted of a crime and the first convicted criminal to be elected to the office.
Those California ex-pats are apparently more than willing to give up the “freedoms” that Newsom holds dear. Subscribe to continue reading this article. Already subscribed? To login in, click here.The China Fund, Inc. Announces Date of Annual Meeting of StockholdersMinnesota looks to stop skid vs. Bethune-Cookman
Vivek Ramaswamy to Axios: DOGE not planning cuts to Social Security, Medicare
Figure Technology Solutions Appoints Macrina Kgil as Chief Financial Officer